Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics entered an exclusive licensing agreement with Everest Medicines for civorebrutinib, a next-generation BTK inhibitor, securing rights for all markets outside China and parts of East/Southeast Asia. The deal includes an upfront payment of $112.5 million and up to $1.03 billion in potential clinical, regulatory, and commercial milestones across up to five indications, plus tiered royalties.
Key figures
- Royalty range
- high single-digit to double-digit percentages
- Upfront payment
- 112500000
- Milestone payments
- 1030000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.